These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 16143170)

  • 41. Executive dysfunction in non-demented Parkinson's disease patients with hallucinations.
    Imamura K; Wada-Isoe K; Kitayama M; Nakashima K
    Acta Neurol Scand; 2008 Apr; 117(4):255-9. PubMed ID: 17922890
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Neuropsychiatric and cognitive symptoms in Parkinson disease].
    Aarsland D; Pedersen KF; Ehrt U; Bronnick K; Gjerstad MD; Larsen JP
    Tidsskr Nor Laegeforen; 2008 Sep; 128(18):2072-6. PubMed ID: 18846124
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis.
    Goetz CG; Emre M; Dubois B
    Ann Neurol; 2008 Dec; 64 Suppl 2():S81-92. PubMed ID: 19127578
    [TBL] [Abstract][Full Text] [Related]  

  • 44. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia.
    Vendette M; Gagnon JF; Décary A; Massicotte-Marquez J; Postuma RB; Doyon J; Panisset M; Montplaisir J
    Neurology; 2007 Nov; 69(19):1843-9. PubMed ID: 17984452
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thalamic atrophy and cognition in multiple sclerosis.
    Houtchens MK; Benedict RH; Killiany R; Sharma J; Jaisani Z; Singh B; Weinstock-Guttman B; Guttmann CR; Bakshi R
    Neurology; 2007 Sep; 69(12):1213-23. PubMed ID: 17875909
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Managing the symptoms of multiple sclerosis: a multimodal approach.
    Crayton HJ; Rossman HS
    Clin Ther; 2006 Apr; 28(4):445-60. PubMed ID: 16750459
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cognitive impairment and neurophysiological correlates in MS.
    Magnano I; Aiello I; Piras MR
    J Neurol Sci; 2006 Jun; 245(1-2):117-22. PubMed ID: 16697015
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cholinergic deficiency in Alzheimer's and Parkinson's disease: evaluation with pupillometry.
    Fotiou DF; Stergiou V; Tsiptsios D; Lithari C; Nakou M; Karlovasitou A
    Int J Psychophysiol; 2009 Aug; 73(2):143-9. PubMed ID: 19414041
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cognitive characteristics associated with mild cognitive impairment in Parkinson's disease.
    McKinlay A; Grace RC; Dalrymple-Alford JC; Roger D
    Dement Geriatr Cogn Disord; 2009; 28(2):121-9. PubMed ID: 19690414
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Measures of cognitive and emotional changes in multiple sclerosis and underlying models of brain dysfunction.
    Gainotti G
    J Neurol Sci; 2006 Jun; 245(1-2):15-20. PubMed ID: 16626747
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Parkinson's disease: the syndrome, the pathogenesis and pathophysiology.
    Bartels AL; Leenders KL
    Cortex; 2009 Sep; 45(8):915-21. PubMed ID: 19095226
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Impact of the cognitive impairment on the quality of life in patients with Parkinson's disease].
    Martínez-Martín P
    Rev Neurol; 2006 Aug 1-15; 43(3):168-72. PubMed ID: 16871482
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cognitive and behavioural impairment in Parkinson's disease.
    Merims D; Freedman M
    Int Rev Psychiatry; 2008 Aug; 20(4):364-73. PubMed ID: 18925485
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Levodopa and cognitive disorders in Parkinson's disease].
    Leiva-Santana C; Alvarez-Saúco M
    Rev Neurol; 2006 Jul 16-31; 43(2):95-100. PubMed ID: 16838257
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pupillometric findings in patients with Parkinson's disease and cognitive disorder.
    Stergiou V; Fotiou D; Tsiptsios D; Haidich B; Nakou M; Giantselidis C; Karlovasitou A
    Int J Psychophysiol; 2009 May; 72(2):97-101. PubMed ID: 19047001
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of individual cognitive profile on visuo-motor reorganization in relapsing-remitting multiple sclerosis.
    Gioia MC; Cerasa A; Liguori M; Passamonti L; Condino F; Vercillo L; Valentino P; Clodomiro A; Quattrone A; Fera F
    Brain Res; 2007 Sep; 1167():71-9. PubMed ID: 17689504
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of non-motor symptoms in advanced Parkinson disease.
    Truong DD; Bhidayasiri R; Wolters E
    J Neurol Sci; 2008 Mar; 266(1-2):216-28. PubMed ID: 17804018
    [TBL] [Abstract][Full Text] [Related]  

  • 58. How pain arises in Parkinson's disease?
    Defazio G; Tinazzi M; Berardelli A
    Eur J Neurol; 2013 Dec; 20(12):1517-23. PubMed ID: 24118186
    [TBL] [Abstract][Full Text] [Related]  

  • 59. White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease.
    Dalaker TO; Larsen JP; Dwyer MG; Aarsland D; Beyer MK; Alves G; Bronnick K; Tysnes OB; Zivadinov R
    Neuroimage; 2009 Oct; 47(4):2083-9. PubMed ID: 19539037
    [TBL] [Abstract][Full Text] [Related]  

  • 60. REM sleep behavior disorder, hallucinations, and cognitive impairment in Parkinson's disease.
    Sinforiani E; Zangaglia R; Manni R; Cristina S; Marchioni E; Nappi G; Mancini F; Pacchetti C
    Mov Disord; 2006 Apr; 21(4):462-6. PubMed ID: 16228998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.